Old Drug Acquires New Target: Metformin and Sirt1
نویسندگان
چکیده
منابع مشابه
Metformin and cancer: new applications for an old drug.
Metformin, one of most widely prescribed oral hypoglycemic agents, has recently received increased attention because of its potential antitumorigenic effects that are thought to be independent of its hypoglycemic effects. Several potential mechanisms have been suggested for the ability of metformin to suppress cancer growth in vitro and vivo: (1) activation of LKB1/AMPK pathway, (2) induction o...
متن کاملMetformin and cancer stem cells: old drug, new targets.
In this issue of the journal, Bao and colleagues report (beginning on page 355) that the antidiabetic drug metformin targets pancreatic cancer stem cells through, at least partially, the modulation of miRNA expression and subsequent regulation of stem cell renewal and signaling factors. In this Perspective, we briefly discuss the cancer stem cell hypothesis, its clinical relevance, and how targ...
متن کاملMetformin revisited – an ‘old’ drug with a ‘new’ beginning
Acting as a weak activator of AMP-activated protein kinase, metformin has established itself as a cost-effective first line agent in the management of type 2 diabetes (T2DM). Besides slowing progression to this condition, its use is associated with improved survival and lower rates of myocardial infarction in T2DM, as well as benefits in stable patients with heart failure. Metformin may play a ...
متن کاملMitotane Revisited: A New Target for an Old Drug.
Adrenocortical carcinoma (ACC) is among the deadliest endocrine malignancies. Radical surgical resection of a localized tumor is the only curative option for ACC, but in many patients cancer is diagnosed already at an advanced stage, needing pharmacological treatment. The mainstay of the medical therapy for metastatic ACC is mitotane (o,p -DDD), a derivative of the insecticide dichlorodiphenyl-...
متن کاملMetformin and its clinical use: new insights for an old drug in clinical practice
Metformin is generally recommended as first-line treatment in type 2 diabetes, especially in overweight patients, but in recent years new indications for its use have emerged. Metformin has been found to be safe and efficacious both as monotherapy and in combination with all oral antidiabetic agents and insulins. If metformin use during pregnancy and the lactation period is supported by few dat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Diabetes & Metabolism
سال: 2011
ISSN: 2155-6156
DOI: 10.4172/2155-6156.1000107e